Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Net Cash Flow: 2020-2025

Historic Net Cash Flow for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -$5.7 million.

  • Insight Molecular Diagnostics' Net Cash Flow rose 3.41% to -$5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year increase of 246.47%. This contributed to the annual value of -$796,000 for FY2024, which is 93.41% up from last year.
  • According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Net Cash Flow is -$5.7 million, which was up 15.87% from -$6.7 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Net Cash Flow registered a high of $51.8 million during Q1 2021, and its lowest value of -$15.2 million during Q1 2022.
  • Moreover, its 3-year median value for Net Cash Flow was -$3.9 million (2024), whereas its average is -$262,545.
  • Over the last 5 years, Insight Molecular Diagnostics' Net Cash Flow had its largest YoY gain of 1,041.85% in 2021, and its largest YoY loss of 5,779.45% in 2021.
  • Over the past 5 years, Insight Molecular Diagnostics' Net Cash Flow (Quarterly) stood at -$7.7 million in 2021, then crashed by 36.39% to -$10.6 million in 2022, then surged by 58.76% to -$4.4 million in 2023, then skyrocketed by 220.71% to $5.3 million in 2024, then grew by 3.41% to -$5.7 million in 2025.
  • Its last three reported values are -$5.7 million in Q3 2025, -$6.7 million for Q2 2025, and $22.4 million during Q1 2025.